<?xml version="1.0" encoding="ISO-8859-1"?><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<front>
<journal-meta>
<journal-id>2794-1140</journal-id>
<journal-title><![CDATA[Pharmaceutical Care España]]></journal-title>
<abbrev-journal-title><![CDATA[Pharm Care Esp.]]></abbrev-journal-title>
<issn>2794-1140</issn>
<publisher>
<publisher-name><![CDATA[Fundación Pharmaceutical Care España]]></publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id>S2794-11402023000400003</article-id>
<article-id pub-id-type="doi">10.60103/phc.v25i4.819</article-id>
<title-group>
<article-title xml:lang="es"><![CDATA[Revisión de medicamentos sin receta con aspartamo: indicación farmacéutica segura en fenilcetonuria]]></article-title>
<article-title xml:lang="en"><![CDATA[Review of non-prescription medicines with aspartame: safe pharmaceutical indication in phenylketonuria]]></article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Hathiramani-Sánchez]]></surname>
<given-names><![CDATA[Mónica]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Palma-López]]></surname>
<given-names><![CDATA[Silvia]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Pizarro-Domínguez]]></surname>
<given-names><![CDATA[Carlos]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Rubio-Armendáriz]]></surname>
<given-names><![CDATA[Carmen]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Hardisson-de-la-Torre]]></surname>
<given-names><![CDATA[Arturo]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[López-Alarcón]]></surname>
<given-names><![CDATA[María Dolores]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
</contrib-group>
<aff id="Af1">
<institution><![CDATA[,Farmacia Gran Chaparral  ]]></institution>
<addr-line><![CDATA[San Bartolomé de Tirajana Las Palmas]]></addr-line>
<country>España</country>
</aff>
<aff id="Af2">
<institution><![CDATA[,Farmacia Gran Chaparral  ]]></institution>
<addr-line><![CDATA[San Bartolomé de Tirajana Las Palmas]]></addr-line>
<country>España</country>
</aff>
<aff id="Af3">
<institution><![CDATA[,Farmacia Brisamar  ]]></institution>
<addr-line><![CDATA[Corralejo Las Palmas]]></addr-line>
<country>España</country>
</aff>
<aff id="Af4">
<institution><![CDATA[,Universidad de La Laguna Facultad de Ciencias de la Salud Área de Toxicología]]></institution>
<addr-line><![CDATA[Santa Cruz de Tenerife ]]></addr-line>
<country>España</country>
</aff>
<aff id="Af5">
<institution><![CDATA[,Universidad de La Laguna Facultad de Ciencias de la Salud Área de Toxicología]]></institution>
<addr-line><![CDATA[Santa Cruz de Tenerife ]]></addr-line>
<country>España</country>
</aff>
<aff id="Af6">
<institution><![CDATA[,Farmacia María Consuelo Cremades Prieto  ]]></institution>
<addr-line><![CDATA[Murcia ]]></addr-line>
<country>España</country>
</aff>
<pub-date pub-type="pub">
<day>00</day>
<month>08</month>
<year>2023</year>
</pub-date>
<pub-date pub-type="epub">
<day>00</day>
<month>08</month>
<year>2023</year>
</pub-date>
<volume>25</volume>
<numero>4</numero>
<fpage>22</fpage>
<lpage>37</lpage>
<copyright-statement/>
<copyright-year/>
<self-uri xlink:href="http://scielo.isciii.es/scielo.php?script=sci_arttext&amp;pid=S2794-11402023000400003&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://scielo.isciii.es/scielo.php?script=sci_abstract&amp;pid=S2794-11402023000400003&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://scielo.isciii.es/scielo.php?script=sci_pdf&amp;pid=S2794-11402023000400003&amp;lng=en&amp;nrm=iso"></self-uri><abstract abstract-type="short" xml:lang="es"><p><![CDATA[Resumen  Introducción: La fenilcetonuria es el trastorno hereditario más frecuente del metabolismo de los aminoácidos y su abordaje suele centrarse en dietas restringidas en fenilalanina, un aminoácido presente en el edulcorante aspartamo habitualmente usado como excipiente en tecnología farmacéutica.  Objetivo: El objetivo principal es la revisión de los medicamentos sin receta comercializados en España hasta marzo de 2023 y que contienen aspartamo en su composición.  Método: Se realizó una revisión en la base de datos BOT plus de todos los medicamentos comercializados en España que contienen aspartamo. Se seleccionaron solo los MSR. Se consultaron las fichas técnicas en el Centro de información online de medicamentos de la AEMPS (CIMA), y los datos obtenidos se registraron en una tabla.  Resultados: Se obtuvieron 570 medicamentos; 58 eran MSR. Cuando exista petición de MSR con aspartamo en pacientes con fenilcetonuria, en el SIF, tras su evaluación, en el 100% de los casos, el farmacéutico aplicando el Servicio de Indicación Farmacéutica podría indicar un MSR alternativo, con el mismo principio activo pero sin aspartamo como excipiente.  Conclusiones: La actuación del farmacéutico comunitario para aplicar el SIF es muy importante en pacientes con fenilcetonuria. Existen medicamentos que no requieren prescripción y se pueden indicar en estos pacientes. El farmacéutico debe tener a su disposición las herramientas necesarias que le faciliten el SIF con este tipo de enfermos.]]></p></abstract>
<abstract abstract-type="short" xml:lang="en"><p><![CDATA[Abstract  Introduction: Phenylketonuria is the most common inherited disorder of amino acid metabolism and its management usually focuses on diets restricted in phenylalanine, an amino acid present in the sweetener aspartame commonly used as an excipient in pharmaceutical technology.  Objective: The main objective is the review of non-prescription medicines marketed in Spain until March 2023 and that contain aspartame in their composition.  Methods: A review of all medicines marketed in Spain containing aspartame was carried out in the BOT plus database. Only MSRs were selected. The data sheets were consulted at the AEMPS online medicines information centre (CIMA), and the data obtained were recorded in a table.  Results: 570 medicines were obtained; 58 were MSRs. When there is a request for MSRs with aspartame in patients with phenylketonuria, in the SIF, after evaluation, in 100% of the cases, the pharmacist applying the Pharmaceutical Indication Service could indicate an alternative MSR, with the same active ingredient but without aspartame as an excipient.  Conclusions: The action of the community pharmacist to apply the SIF is very important in patients with phenylketonuria. There are medicines that do not require a prescription and can be prescribed for these patients. Pharmacists should have the necessary tools at their disposal to facilitate the SIF with this type of patient.]]></p></abstract>
<kwd-group>
<kwd lng="es"><![CDATA[Fenilcetonuria]]></kwd>
<kwd lng="es"><![CDATA[Aspartamo]]></kwd>
<kwd lng="es"><![CDATA[Excipiente]]></kwd>
<kwd lng="es"><![CDATA[Seguridad del paciente]]></kwd>
<kwd lng="es"><![CDATA[Medicamentos sin receta]]></kwd>
<kwd lng="en"><![CDATA[Phenylketonuria]]></kwd>
<kwd lng="en"><![CDATA[Aspartame]]></kwd>
<kwd lng="en"><![CDATA[Excipient]]></kwd>
<kwd lng="en"><![CDATA[Patient safety]]></kwd>
<kwd lng="en"><![CDATA[Over-the-counter drugs]]></kwd>
</kwd-group>
</article-meta>
</front><back>
<ref-list>
<ref id="B1">
<label>1</label><nlm-citation citation-type="book">
<collab>Grupo de trabajo de protocolos de cribado neonatal de la Ponencia de cribado poblacional</collab>
<source><![CDATA[Protocolo de cribado neonatal de la fenilcetonuria]]></source>
<year>2021</year>
<publisher-name><![CDATA[Ministerio de Sanidad]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B2">
<label>2</label><nlm-citation citation-type="journal">
<collab>European Food Safety Authority</collab>
<article-title xml:lang=""><![CDATA[Scientific Opinion on the re-evaluation of aspartame (E 951) as a food additive]]></article-title>
<source><![CDATA[EFSA J]]></source>
<year>2013</year>
<volume>11</volume>
<numero>12</numero>
<issue>12</issue>
</nlm-citation>
</ref>
<ref id="B3">
<label>3</label><nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Costa Lathan]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
</person-group>
<source><![CDATA[Valoración neurocognitiva en pacientes con fenilcetonuria]]></source>
<year>2020</year>
<publisher-name><![CDATA[Universidad Santiago de Compostela]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B4">
<label>4</label><nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Carnero Gómez]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
</person-group>
<source><![CDATA[Aspartamo: un edulcorante polémico]]></source>
<year>2013</year>
<publisher-name><![CDATA[Farmacia Luis Marcos]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B5">
<label>5</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Cavagnari]]></surname>
<given-names><![CDATA[BM]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Edulcorantes no calóricos: características específicas y evaluación de su seguridad]]></article-title>
<source><![CDATA[Arch Argent Pediatr]]></source>
<year>2019</year>
<volume>117</volume>
<numero>1</numero>
<issue>1</issue>
</nlm-citation>
</ref>
<ref id="B6">
<label>6</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Guerrero Villegas]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Mora Flores]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Posibles riesgos para la salud debido al consumo de aspartame]]></article-title>
<source><![CDATA[Enfoque UTE]]></source>
<year>2014</year>
<volume>5</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>1-13</page-range></nlm-citation>
</ref>
<ref id="B7">
<label>7</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Magnuson]]></surname>
<given-names><![CDATA[BA]]></given-names>
</name>
<name>
<surname><![CDATA[Carakostas]]></surname>
<given-names><![CDATA[MC]]></given-names>
</name>
<name>
<surname><![CDATA[Moore]]></surname>
<given-names><![CDATA[NH]]></given-names>
</name>
<name>
<surname><![CDATA[Poulos]]></surname>
<given-names><![CDATA[SP]]></given-names>
</name>
<name>
<surname><![CDATA[Renwick]]></surname>
<given-names><![CDATA[AG]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Biological fate of low-calorie sweeteners]]></article-title>
<source><![CDATA[Nutr Rev]]></source>
<year>2016</year>
<volume>74</volume>
<numero>11</numero>
<issue>11</issue>
<page-range>670-89</page-range></nlm-citation>
</ref>
<ref id="B8">
<label>8</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Pifferi]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Restani]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The safety of pharmaceutical excipients]]></article-title>
<source><![CDATA[Fármaco]]></source>
<year>2003</year>
<volume>58</volume>
<numero>8</numero>
<issue>8</issue>
<page-range>541-50</page-range></nlm-citation>
</ref>
<ref id="B9">
<label>9</label><nlm-citation citation-type="book">
<collab>AEMPS</collab>
<source><![CDATA[Actualización de la información sobre excipientes en la información de medicamentos]]></source>
<year></year>
<publisher-name><![CDATA[Ministerio de Sanidad, Consumo y Bienestar Social]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B10">
<label>10</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Balbani]]></surname>
<given-names><![CDATA[APS]]></given-names>
</name>
<name>
<surname><![CDATA[Stelzer]]></surname>
<given-names><![CDATA[LB]]></given-names>
</name>
<name>
<surname><![CDATA[Montovani]]></surname>
<given-names><![CDATA[JC]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Pharmaceutical excipients and the information on drug labels]]></article-title>
<source><![CDATA[Braz J Otorhinolaryngol]]></source>
<year>2006</year>
<volume>72</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>400-6</page-range></nlm-citation>
</ref>
<ref id="B11">
<label>11</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Newbould]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Pinto]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Evans]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Ford]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[O'Driscoll]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Ashmore]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Accidental Consumption of Aspartame in Phenylketonuria: Patient Experiences]]></article-title>
<source><![CDATA[Nutrients]]></source>
<year>2021</year>
<volume>13</volume>
<numero>2</numero>
<issue>2</issue>
</nlm-citation>
</ref>
<ref id="B12">
<label>12</label><nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Martínez-Martínez]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Gastelurrutia]]></surname>
<given-names><![CDATA[MA]]></given-names>
</name>
<name>
<surname><![CDATA[Farragher]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Faus]]></surname>
<given-names><![CDATA[MJ]]></given-names>
</name>
<name>
<surname><![CDATA[García]]></surname>
<given-names><![CDATA[MV]]></given-names>
</name>
<name>
<surname><![CDATA[Jódar]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
</person-group>
<source><![CDATA[Medida del Impacto del impacto clínico, económico y humanístico del servicio de seguimiento farmacoterapétuico en mayores polimedicados, en la farmacia comunitaria española]]></source>
<year>2014</year>
<publisher-loc><![CDATA[Madrid ]]></publisher-loc>
<publisher-name><![CDATA[CGCOF]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B13">
<label>13</label><nlm-citation citation-type="confpro">
<collab>Consejo General de Colegios Oficiales de Farmacéuticos</collab>
<source><![CDATA[Guía práctica para los Servicios Profesionales Farmacéuticos Asistenciales en la Farmacia Comunitaria]]></source>
<year>2019</year>
<conf-name><![CDATA[ Foro de Atención Farmacéutica-Farmacia Comunitaria (Foro AF-FC)]]></conf-name>
<conf-loc> </conf-loc>
<publisher-loc><![CDATA[Madrid ]]></publisher-loc>
<publisher-name><![CDATA[Consejo General de Colegios Oficiales de Farmacéuticos]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B14">
<label>14</label><nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Faus Dáder]]></surname>
<given-names><![CDATA[MJ]]></given-names>
</name>
<name>
<surname><![CDATA[Amariles Muñoz]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Martínez-Martínez]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
</person-group>
<source><![CDATA[Atención Farmacéutica: conceptos, procesos y casos prácticos]]></source>
<year>2008</year>
<publisher-loc><![CDATA[Madrid ]]></publisher-loc>
<publisher-name><![CDATA[Ergon]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B15">
<label>15</label><nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Faus Dáder]]></surname>
<given-names><![CDATA[MJ]]></given-names>
</name>
<name>
<surname><![CDATA[Gómez Martínez]]></surname>
<given-names><![CDATA[JC]]></given-names>
</name>
<name>
<surname><![CDATA[Martínez Martínez]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
</person-group>
<source><![CDATA[Protocolos de indicación farmacéutica y criterios de derivación al Médico en Síntomas Menores]]></source>
<year>2008</year>
<publisher-loc><![CDATA[Granada ]]></publisher-loc>
<publisher-name><![CDATA[Editorial Técnica AVICAM]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B16">
<label>16</label><nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Stanley]]></surname>
<given-names><![CDATA[Lesley]]></given-names>
</name>
</person-group>
<source><![CDATA[Review of data on the food additive aspartame]]></source>
<year>2013</year>
<publisher-name><![CDATA[European Food Safety Authority]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B17">
<label>17</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Sáez-Benito]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Fernandez-Llimos]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Feletto]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Gastelurrutia]]></surname>
<given-names><![CDATA[MA]]></given-names>
</name>
<name>
<surname><![CDATA[Martinez-Martinez]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Benrimoj]]></surname>
<given-names><![CDATA[SI]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Evidence of the clinical effectiveness of cognitive pharmaceutical services for aged patients]]></article-title>
<source><![CDATA[Age Ageing]]></source>
<year>2013</year>
<volume>42</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>442-9</page-range></nlm-citation>
</ref>
<ref id="B18">
<label>18</label><nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Varas Doval]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
</person-group>
<source><![CDATA[Implantación del Seguimiento Farmacoterapéutico como Servicio Profesional Farmacéutico Asistencial en la Farmacia Comunitaria española y su Impacto sobre los Resultados en Salud]]></source>
<year>2021</year>
<publisher-name><![CDATA[Universidad de Granada]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B19">
<label>19</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Oñatibia-Astibia]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Aizpurua-Arruti]]></surname>
<given-names><![CDATA[X]]></given-names>
</name>
<name>
<surname><![CDATA[Malet-Larrea]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Gastelurrutia]]></surname>
<given-names><![CDATA[MA]]></given-names>
</name>
<name>
<surname><![CDATA[Goyenechea]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[El papel del farmacéutico comunitario en la detección y disminución de los errores de medicación: revisión sistemática exploratoria]]></article-title>
<source><![CDATA[Ars Pharm]]></source>
<year>2021</year>
<volume>62</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>15-39</page-range></nlm-citation>
</ref>
<ref id="B20">
<label>20</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Pizarro Domínguez]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Hathiramani Sánchez]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Rubio Armendáriz]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Hardisson de la Torre]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Especialidades Farmacéuticas Publicitarias con excipientes azoicos: guía para la prevención del uso inseguro en dispensación e indicación farmacéutica]]></article-title>
<source><![CDATA[Pharm Care Esp]]></source>
<year>2021</year>
<volume>23</volume>
<numero>6</numero>
<issue>6</issue>
<page-range>6-18</page-range></nlm-citation>
</ref>
</ref-list>
</back>
</article>
